Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Vaprisol
Synonyms :
conivaptan
Class :
Vasopressin-Related
Brand Name :
Vaprisol
Synonyms :
conivaptan
Class :
Vasopressin-Related
Dosage forms & Strengths:Â
Adult:Â
Premixed solution for InjectionÂ
5 mg/ml (20mg/100mL D5W)Â
Safety and efficacy are not seen in pediatricsÂ
Premixed solution for InjectionÂ
5 mg/ml (20mg/100mL D5W)Â
It may enhance the effect when combined with irinotecan liposomal by affecting CYP3A4 metabolism
when both drugs are combined, there may be an increased effect of conivaptan by affecting hepatic or intestinal enzyme cyp3a4 metabolism  
by affecting intestinal metabolism, the effect of conivaptan may be increased
when both drugs are combined, there may be an increased effect of cabozantinib by affecting hepatic or intestinal enzyme cyp3a4 metabolism  
the effect of conivaptan is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
It may diminish the effect when combined with griseofulvin by CYP3A4 metabolism
It may enhance the levels when combined with tamsulosin by affecting CYP3A4 metabolism
may enhance the hyperkalemic effect
may enhance the hyperkalemic effect
may enhance the hyperkalemic effect
may enhance the hyperkalemic effect
may enhance the hyperkalemic effect
may enhance the hyperkalemic effect
may enhance the hyperkalemic effect
may enhance the hyperkalemic effect
may enhance the hyperkalemic effect
may enhance the hyperkalemic effect
spironolactone and hydrochlorothiazide
may enhance the hyperkalemic effect
may enhance the hyperkalemic effect
may enhance the hyperkalemic effect
may enhance the hyperkalemic effect
may enhance the hyperkalemic effect
it may enhance the metabolism when combined with oxcarbazepine
When alprazolam and conivaptan is used together, this leads to reduction in the alprazolam’s metabolism
conivaptan: they may enhance the serum concentration of CYP3A4 Inhibitors
conivaptan: they may enhance the serum concentration of CYP3A4 Inhibitors
conivaptan: they may enhance the serum concentration of CYP3A4 Inhibitors
conivaptan: they may enhance the serum concentration of CYP3A4 Inhibitors
conivaptan: they may enhance the serum concentration of CYP3A4 Inhibitors
When conivaptan is used together with ridaforolimus, this leads to enhanced concentration serum of conivaptan
when both drugs combine conivaptan will increase the effect of ifosfamide by affecting the enzyme CYP3A4 metabolism.
it increases by affecting the hepatic enzyme CYP3A4 metabolism
may decrease the serum concentration
may decrease the serum concentration
may decrease the serum concentration
may decrease the serum concentration
may decrease the serum concentration
may decrease the serum concentration
may decrease the serum concentration
may decrease the serum concentration
may decrease the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
the risk of dehydration can be increased
When conivaptan is used together with oliceridine, this leads to enhanced concentration serum of oliceridine
Actions and Spectrum:Â
conivaptan works by blocking the action of a hormone called vasopressin, which helps regulate the balance of fluids in the body. conivaptan is used to treat hyponatremia in hospitalized patients. It is typically given as an intravenous injection, and its effects typically last for about 24 hours.Â
>10%:Â
Infusion site reactions (20.2%)Â
Infusion site phlebitis (15.8%)Â
Headache (12%)Â
1-10%:Â
HypotensionÂ
AnemiaÂ
Dry mouthÂ
DehydrationÂ
ConstipationÂ
ThirstÂ
NauseaÂ
DiarrheaÂ
HematuriaÂ
PolyuriaÂ
PollakiuriaÂ
HyperglycemiaÂ
Urinary Tract InfectionÂ
Pain Â
PneumoniaÂ
PhlebitisÂ
Oral candidiasisÂ
PyrexiaÂ
Black Box Warning:Â
It is essential to follow the dosage and administration instructions for the medication carefully.
Contraindication/Caution:Â
conivaptan should not be used in people hypersensitive to the drug itself. Â
Pregnancy consideration:Â Â
No data is available regarding the usage of the drug during pregnancy.Â
Breastfeeding warnings:Â Â
No data is available regarding the presence of the drug in breast milk.Â
Pregnancy category:Â
PharmacologyÂ
conivaptan is a synthetic non-peptide competitive antagonist of the arginine vasopressin (AVP) V1A and V2 receptors. The V1A receptor is found in the vascular smooth muscle, and the V2 receptors are found in the renal collecting ducts and medullary interstitial cells. By blocking the action of AVP on these receptors, conivaptan increases the excretion of water from the body and raises blood sodium levels.Â
Pharmacodynamics:Â
conivaptan is a non-peptide competitive antagonist of the arginine vasopressin (AVP) V1A and V2 receptors. By binding to and blocking these receptors, conivaptan prevents the typical actions of AVP in the body.Â
Pharmacokinetics:Â Â
Pharmacokinetics studies how a drug is absorbed, distributed, metabolized, and eliminated by the body.Â
AbsorptionÂ
conivaptan is administered as an intravenous (IV) injection and is rapidly absorbed into the bloodstream. The bioavailability of conivaptan is 100% when given IV.Â
DistributionÂ
conivaptan has a large volume of distribution (about 4 L/kg) and is highly protein-bound (about 98%)Â
MetabolismÂ
conivaptan is metabolized primarily by the liver, and the primary metabolite is conivaptan N-oxide. The metabolism of conivaptan is mediated by cytochrome P450 3A4 (CYP3A4) enzyme.Â
Elimination and excretionÂ
conivaptan is eliminated primarily by the kidneys, and the elimination half-life is about 3.5 hours. The elimination of conivaptan and its metabolite is consistent with linear pharmacokinetics.Â
Administration:Â
conivaptan is used by making the solution with dextrose 5%. Loading dose over 30 minutes and continuous infusion over 24 hours.Â
Patient information leafletÂ
Generic Name: conivaptanÂ
Pronounced: coni-vap-tanÂ
Why do we use conivaptan?Â
conivaptan is used to replenish hyponatremia. Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
